ArticleACS omega2025
Involvement of Integrated Stress Response in Drug-Induced Secondary Dystonia.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A maladaptive integrated stress response (ISR) involving dysregulation of eukaryotic translation initiation factor α (eIF2α) signaling is observed in several types of inherited primary dystonia. In the case of secondary dystonia resulting as a side effect of various antipsychotic and antiemetic drugs, the involved molecular pathways have not been characterized. In this study, we investigated the contribution of the ISR pathway to drug-induced dystonia. Using murine neuroblastoma-derived Neuro-2a (N2a) cells, we investigated the ability of antipsychotic drugs to induce ISR. We tested eight drugs reported in the literature to cause dystonia as a side effect. After the N2a cells were treated with these drugs at their reported plasma concentrations, the cell extracts were analyzed for ISR induction by Western blot analyses. The involvement of PKR (protein kinase, RNA-activated) and PACT (PKR activator) was evaluated by coimmunoprecipitation analyses, and the ability of luteolin to disrupt the PACT-PKR interaction to suppress ISR induction was tested by coimmunoprecipitation and Western blot analyses. Our results indicate that the antipsychotic drugs induce ISR by activating PERK (PKR-like endoplasmic reticulum resident kinase) as well as PKR, resulting in eIF2α phosphorylation. PACT associates with PKR after exposure to antipsychotic drugs, causing PKR activation, and luteolin disrupts the PACT-PKR interaction to suppress ISR. Based on our studies, ISR induction is identified as a pathomechanism for secondary dystonia for the first time, and luteolin can be explored further for its ability to suppress ISR and avoid or alleviate secondary drug-induced dystonia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.